Oxygen Therapy for Retinal Ischemia
Phase 4
Withdrawn
- Conditions
- Retinal Ischemia
- Interventions
- Drug: Hyperoxia
- Registration Number
- NCT03730779
- Lead Sponsor
- Beth Israel Deaconess Medical Center
- Brief Summary
The investigators will be using nocturnal normobaric hyperoxia therapy in patients with diagnoses of conditions related to retinal ischemia.
- Detailed Description
Patients who receive a diagnosis of a condition relate to retinal ischemia and who pass the eligibility criteria will receive an oxygen concentrator to use at home. They will report back in follow up monthly for three to six months.
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- Diagnosis of retinal-ischemia related condition
Exclusion Criteria
- Complicating other ocular condition
- History of smoking or lung conditions
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description O2 recieving Hyperoxia Patients who receive hyperoxia
- Primary Outcome Measures
Name Time Method Macula Edema 6 months Amount of ME present, as measured by OCT
Best Corrected Visual Acuity 6 months Best Corrected Visual Acuity as measured by ETDRS chart
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Beth Israel Deaconess Medical Center
🇺🇸Boston, Massachusetts, United States